Cardiol Therapeutics | Finanzwire

Basculer en Français

11083	Companies
243279	Keywords
171456	Articles
131014	Press releases

Home
Companies
Cardiol Therapeutics

PRESS RELEASE

published on 02/27/2024 at 14:16, 2 years 6 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
BRIEF

published on 02/27/2024 at 14:16, 2 years 6 months ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
PRESS RELEASE

published on 01/19/2024 at 12:41, 2 years 8 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential
PRESS RELEASE

published on 08/30/2023 at 15:06, 3 years ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 05/24/2023 at 13:01, 3 years 4 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 04/11/2023 at 15:26, 3 years 5 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy

Accesswire

Published on 09/26/2026 at 01:00, 10 hours 16 minutes ago

Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 10 hours 16 minutes ago

Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 13 hours 1 minute ago

Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 17 hours 46 minutes ago

Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 20 hours 16 minutes ago

HM Exploration Provides Program Update for the Lewis Pilley's Project

View all ACCESSWIRE

EQS Group

Published on 09/26/2026 at 07:45, 3 hours 31 minutes ago

Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 11 hours 15 minutes ago

Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 16 hours 46 minutes ago

029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:15, 17 hours 1 minute ago

Warren Wise decodes Qiagen’s DNA
Published on 09/25/2026 at 17:30, 17 hours 46 minutes ago

GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)

Les Echos

Published on 09/25/2026 at 17:40, 17 hours 36 minutes ago

Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:10, 1 day 17 hours ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 1 day 17 hours ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 1 day 17 hours ago

GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 1 day 17 hours ago

Cegedim first-half 2026 results: profitability continues to improve

View all LES ECHOS COMFI WIRE